Skip to main content
Premium Trial:

Request an Annual Quote

Looking for the Back Door

Chemical and pharmaceutical conglomerate Solvay is looking for a way out of the pharma business, reports the Wall Street Journal. The Belgian company said yesterday that it is looking into "various options for its pharmaceutical activities" including "discussions with third parties." The WSJ estimates that the pharmaceutical division could be worth $6.6 billion and says that potential buyers include Abbott Laboratories, AstraZeneca, Bayer, Merck KGaA of Germany, and Sanofi-Aventis.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.